QT
CTMX icon

Quantamental Technologies’s CytomX Therapeutics CTMX Stock Holding History

Quantamental Technologies’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-713
Closed -$8K – 1576
2019
Q2 		$8K Buy
+713
New +$7.47K ﹤0.01% 1276
2019
Q1 		– Sell
-878
Closed -$13K – 1534
2018
Q4 		$13K Buy
+878
New +$13K 0.01% 1097

Other funds holding CTMX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Quantamental Technologies's CTMX Position: Q3 2019 in Review

Quantamental Technologies sold out of CytomX Therapeutics (CTMX) in Q3 2019, closing a stake of 713 shares — an estimated $8K sold.

Quantamental Technologies first reported a position in CTMX in Q4 2018 and held it in 2 quarters. The position peaked at $13K in Q4 2018. 113 funds tracked by Wall St. Rank hold CTMX as of Q3 2019.

  • Quantamental Technologies reported no remaining CytomX Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Quantamental Technologies sold 713 CytomX Therapeutics shares in Q3 2019, an estimated $8K.
  • Quantamental Technologies first reported a position in CytomX Therapeutics in Q4 2018 and held it in 2 quarters.
  • Quantamental Technologies's CytomX Therapeutics position peaked at $13K in Q4 2018.
  • 113 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2019.

Based on Quantamental Technologies's 13F filing for Q3 2019, filed 8 Nov 2019.